At a recent international academic conference on breast cancer, Professor Claudio Vernieri from the University of Milan and the Fondazione IRCCS Istituto Nazionale dei Tumori shared the latest results of the multicenter, real-world study PALMARES-2. The study focuses on patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). It explores the clinical benefits and patient characteristics associated with continuing the original treatment regimen ("Treatment Beyond Progression," TBP) after experiencing disease progression (PD) on first-line endocrine therapy (ET) combined with a CDK4/6 inhibitor (CDK4/6i), providing an important reference for the TBP strategy in clinical practice.

In the evolution of treatment for Multiple Myeloma (MM), moving highly effective therapies forward to the early stages of the disease has become a current research hotspot. For patients with High-Risk Smoldering Multiple Myeloma (HR SMM), whether early active intervention can delay or even prevent its transformation into active myeloma is a focus of clinical attention. At a recent international academic conference, Professor Cyrille Touzeau from the University Hospital of Nantes in France shared the preliminary results of the ERASMM (EMN34) study. This study aimed to evaluate the safety and efficacy of the BCMA×CD3 bispecific antibody Elranatamab in patients with HR SMM. This journal has specially compiled the highlights of the conference for our readers.

In the field of relapsed/refractory classical Hodgkin lymphoma (R/R cHL), although the application of immune checkpoint inhibitors (such as anti-PD-1) and antibody-drug conjugates (such as Brentuximab Vedotin, BV) has significantly improved patient prognosis, clinical challenges remain severe for patients who fail multiple lines of therapy. Recently, at an international academic conference, Professor Enrico Derenzini, on behalf of the PRIMAVERA research team, shared the Phase I study results of the PRMT5 inhibitor AZD3470 in patients with R/R cHL. This journal has summarized the key points of the meeting to provide a deep analysis of this innovative therapy targeting MTAP deficiency and utilizing the "synthetic lethality" mechanism, representing a latest breakthrough in the field of hematologic malignancies.

At a recent international oncology symposium, Professor François-Clément Bidard from Institut Curie shared the updated results from the third data cut-off (DCO3) of the Phase III SERENA-6 study. The study focuses on patients with HR+/HER2- advanced breast cancer (ABC). During first-line treatment with an aromatase inhibitor (AI) combined with a CDK4/6 inhibitor (CDK4/6i), once a new-onset ESR1 mutation is detected via circulating tumor DNA (ctDNA) monitoring, the AI is immediately switched to Camizestrant, a novel oral selective estrogen receptor degrader (SERD), to assess clinical benefit. This report highlights key secondary endpoints—the final progression-free survival 2 (PFS2) and core data such as ctDNA kinetics analysis.

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma (NHL). Although the R-CHOP regimen has established its position as the cornerstone of first-line treatment, approximately 40% of high-risk patients still face the dilemma of refractory or relapsed disease. At a recent academic conference, Professor Georg Lenz from University Hospital Münster, Germany, on behalf of the research team, released the latest data from the frontMIND study (NCT04824092), exploring the clinical benefits of the anti-CD19 monoclonal antibody Tafasitamab (Tafa) combined with Lenalidomide (Len) and the R-CHOP regimen in patients with previously untreated high-risk DLBCL.

At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Ida Wong-Sefidan (MD) from the AIDS Malignancy Consortium (AMC), on behalf of the research team, shared a milestone study. This study aimed to evaluate the clinical benefits of the Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib in combination with dose-adjusted R-EPOCH (R-da-EPOCH) for the treatment of Human Immunodeficiency Virus-associated Diffuse Large B-cell Lymphoma (HIV-DLBCL). The study results not only confirmed the safety of the regimen but also provided critical data support in terms of efficacy and subgroup survival analysis.

In the field of surgical treatment for breast cancer, the trend of "de-escalation" in axillary management has become a consensus. Although studies such as ACOSOG Z011 and AMAROS have laid the foundation for exempting axillary lymph node dissection (ALND) in patients with positive sentinel lymph nodes (SLN), controversy remains in clinical practice regarding whether it is safe to exempt ALND for patients undergoing total mastectomy, patients with large tumors (T3), and those with macrometastases. At this conference, Professor Jana de Boniface from Karolinska Institutet and Capio St. Göran Hospital in Sweden presented the highly anticipated latest results of the SENOMAC trial, a randomized controlled study focusing on survival data and patient-reported arm complications after exempting ALND in patients with SLN macrometastases.

At a recent international breast cancer academic conference, Professor Nicholas C. Turner from The Royal Marsden Hospital and the Institute of Cancer Research (ICR) in the UK presented the highly anticipated primary analysis results of the Phase III persevERA BC study. This study aimed to evaluate the efficacy and safety of a novel oral selective estrogen receptor degrader (SERD), Giredestrant (GIRE), in combination with the CDK4/6 inhibitor Palbociclib (PALBO), compared to the standard aromatase inhibitor (AI) Letrozole (LET) plus Palbociclib, in the first-line treatment of estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in grand fashion in Chicago, showcasing numerous highlights and breakthroughs in gastrointestinal oncology. On this occasion, Oncology Frontier invited Prof. Yinying Wu from the First Affiliated Hospital of Xi’an Jiaotong University to share her perspectives and discuss the impressive contributions of Chinese investigator-initiated research presented at this year’s meeting.